We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current SNT market cap is 37.58M. The company's latest EPS is AUD -0.0210 and P/E is -2.38.
| Year End June 29 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Total Revenue | 7.03M | 22.65M | 9.77M | 12.96M | 546k |
| Operating Income | -15.83M | -3.7M | -14.44M | -11.86M | -20.98M |
| Net Income | -13.94M | -2.97M | -1.94M | -11.36M | -15.14M |
| Year End June 29 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Total Assets | 35.42M | 33.59M | 25.19M | 24.03M | 10.38M |
| Total Liabilities | 33.99M | 30.75M | 14.38M | 14.47M | 5.7M |
| Total Equity | 1.43M | 2.85M | 10.8M | 9.56M | 4.68M |
| Year End June 29 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Operating | -13.28M | 3.07M | -16.1M | -7.28M | -14.48M |
| Investing | -574k | -644k | -306k | -131k | 1.49M |
| Financing | -2.5M | 1.52M | 6.63M | 6.98M | 7.2M |
| Market Cap | 37.58M |
| Price to Earnings Ratio | -2.38 |
| Price to Sales Ratio | 62.5 |
| Price to Cash Ratio | 10.2 |
| Price to Book Ratio | 7.72 |
| Dividend Yield | - |
| Shares Outstanding | 722.61M |
| Average Volume (1 week) | 4.94M |
| Average Volume (1 Month) | 5.25M |
| 52 Week Change | 225.00% |
| 52 Week High | 0.095 |
| 52 Week Low | 0.014 |
| Spread (Intraday) | 0 (3.77%) |
| Company Name | Syntara Ltd |
| Address |
20 rodborough road sydney, new south wales 2086 |
| Website | https://www.pharmaxis.com.au |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
